公开(公告)号：US09649310B2

公开(公告)日：2017-05-16

申请号：US15042964

申请日：2016-02-12

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson

IPC: A61K31/506 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/513

CPC classification number: A61K31/506 ,  A61K31/505 ,  A61K31/513 ,  A61K31/5377 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US09562021B2

公开(公告)日：2017-02-07

申请号：US14776039

申请日：2014-03-10

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Vahri Beaumont ,  Ignacio Muñoz-Sanjuán ,  Roland W. Bürli ,  Alan F. Haughan ,  Christopher A. Luckhurst ,  Michael Wall ,  Gilles Raphy ,  Beth Thomas

IPC: C07D239/26 ,  A61K31/505

CPC classification number: A61K31/505 ,  C07D239/26

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

Abstract translation: 提供式I的组蛋白脱乙酰酶（HDAC）抑制剂，其组合物及其使用方法。

公开(公告)号：US20160024019A1

公开(公告)日：2016-01-28

申请号：US14776039

申请日：2014-03-10

Applicant: CHDI FOUNDATION, INC.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Vahri Beaumont ,  Maria Beconi ,  Roland W. Bürli ,  Alan F. Haughan ,  Christopher A. Luckhurst ,  Michael Wall ,  Gilles Raphy ,  Beth Thomas

IPC: C07D239/26

CPC classification number: A61K31/505 ,  C07D239/26

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

公开(公告)号：US11110154B2

公开(公告)日：2021-09-07

申请号：US14706747

申请日：2015-05-07

Applicant: Sangamo BioSciences, Inc. ,  CHDI Foundation, Inc.

Inventor： Steven Froelich ,  Seung Kwak ,  Ignacio Munoz-Sanjuan ,  H. Steve Zhang

IPC: A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/28 ,  C07K19/00 ,  C12N15/62 ,  C12N15/86 ,  A61K38/54 ,  A61K38/46 ,  A61K38/18 ,  A61K38/17 ,  C12N15/864 ,  C12N15/63

Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.

公开(公告)号：US11104691B2

公开(公告)日：2021-08-31

申请号：US15507203

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Alex Kiselyov ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Daniel Clark-Frew

IPC: A61K51/00 ,  A61M36/14 ,  C07D519/00 ,  C07D471/04 ,  A61K51/04

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10765764B2

公开(公告)日：2020-09-08

申请号：US16172425

申请日：2018-10-26

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Thomas Martin Krulle ,  Daniel Clark-Frew ,  Duane Higgins ,  Matthew Robert Mills ,  Richard Waldron Marston ,  Samuel Coe ,  Samantha Brown ,  Sarah Hayes

IPC: A61K51/04 ,  C07D513/04 ,  C07D487/04 ,  C07D513/14 ,  C07B59/00

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US20200276176A1

公开(公告)日：2020-09-03

申请号：US16799651

申请日：2020-02-24

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Jonathan Bard ,  Matthew R. Lee ,  Longbin Liu ,  Michael Edward Prime ,  Samuel Coe

IPC: A61K31/454 ,  A61K31/427 ,  A61K31/165 ,  A61K47/54

Abstract: The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

公开(公告)号：US10457675B2

公开(公告)日：2019-10-29

申请号：US16049482

申请日：2018-07-30

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Roland W. Bürli ,  Christopher A. Luckhurst ,  Daniel R. Allen ,  Gilles Raphy ,  Perla Breccia ,  Alan F. Haughan ,  Grant Wishart ,  Samantha J. Hughes ,  Rebecca E. Jarvis ,  Huw D. Vater ,  Stephen D. Penrose ,  Michael Wall ,  Andrew J. Stott ,  Elizabeth A. Saville-Stones

IPC: C07D417/04 ,  C07D231/54 ,  C07D401/04 ,  C07D403/04 ,  C07D239/70 ,  C07D239/74 ,  C07D239/88 ,  C07D277/60 ,  C07C259/08 ,  C07D231/56 ,  C07D275/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.

公开(公告)号：US10442782B2

公开(公告)日：2019-10-15

申请号：US15813001

申请日：2017-11-14

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Leonard Mitchell ,  Peter Johnson ,  Naomi Went

IPC: C07D311/20 ,  C07D307/79 ,  C07D263/58 ,  C07D235/26 ,  C07D319/18 ,  C07D317/46 ,  C07D215/18 ,  C07C62/38 ,  C07D307/94 ,  C07D309/10 ,  C07D311/58 ,  C07D317/60 ,  C07D233/64 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07C317/44 ,  C07D413/08 ,  C07D413/10 ,  C07C323/62 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07D257/04 ,  C07D203/08 ,  C07C235/82 ,  C07D207/08 ,  C07D271/07 ,  C07D207/337 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/80 ,  C07C69/757 ,  C07D203/10 ,  C07D413/12 ,  C07H15/20

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20190167821A1

公开(公告)日：2019-06-06

申请号：US16172425

申请日：2018-10-26

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Thomas Martin Krulle ,  Daniel Clark-Frew ,  Duane Higgins ,  Matthew Robert Mills ,  Richard Waldron Marston ,  Samuel Coe ,  Samantha Brown ,  Sarah Hayes

IPC: A61K51/04 ,  C07B59/00 ,  C07D513/04 ,  C07D487/04 ,  C07D513/14

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.